摘要
目的:观察口服利奈唑胺片治疗年龄≥80岁的高龄心力衰竭合并肺炎患者的临床疗效稳定性与安全性。方法:针对我院2018年1月—2019年12月就诊的年龄≥80岁的56例高龄老年心力衰竭合并肺部感染病例做回顾性分析,统计患者治疗前后的白细胞、中性粒细胞计数、C反应蛋白(CRP)、降钙素原(PCT)指标变化水平波动情况来评估疗效,同时统计肝功能、肾功能、血小板指标变化情况,评估药物的安全性。结果:患者治疗前后的白细胞、中性粒细胞计数、CRP均下降,抗感染治疗效果明确,而PCT升高,但P>0.05,无统计学意义;治疗前后的肝功能、肾功能指标有变化,但P>0.05,无统计学意义,血小板水平下降明显且有统计学意义,血小板下降为主要副作用。结论:在对高龄心力衰竭合并肺炎患者治疗期间,既要提高治疗效果,也要兼顾药物的安全性,选择口服利奈唑胺片剂治疗,疗效肯定且副作用可控,用于治疗高龄患者的危重型感染值得临床推广。
Objective:To observe the clinical efficacy stability and safety of oral linezolid tablets in the treatment of elderly patients with heart failure ≥80 years old with pneumonia.Methods:A retrospective analysis of 56 elderly patients with heart failure and pulmonary infections aged ≥80 years old who visited our hospital from January 2018 to December 2019 was performed.The white blood cell,neutrophil count,C-reactive protein (CRP) and procalcitonin (PCT) before and after treatment were used to evaluate clinical efficacy.At the same time,the changes in liver function,kidney function and platelet indexes of patients after treatment were counted to evaluate the safety of the drug.Results:The white blood cell count,neutrophil count,and CRP in patients before and after treatment were all decreased,the anti-inflammatory treatment effect was clear,and PCT was increased,but P>0.05 was not statistically significant;liver function and kidney function indicators before and after treatment There is a change,but P>0.05 is not statistically significant,the platelet level drops significantly and statistically,and platelet is the main side effect.Conclusion:During the treatment of elderly patients with heart failure and pneumonia,it is necessary to improve the treatment effect and take into account the safety of the drug.The choice of oral linezolid tablets is effective and the side effects are controllable.It is worthwhile for the treatment of critically ill infections in elderly patients.
作者
王乐
石斗飞
WANG Le;SHI Dou-fei(Binzhou Medical University,Shandong Yantai 264033;Affiliated Hospital of Binzhou Medical University,Shandong Binzhou 256603)
出处
《中国药物滥用防治杂志》
CAS
2020年第6期357-360,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
老年性肺炎
利奈唑胺
口服制剂
临床疗效
用药安全
senile pneumonia
linezolid
oral preparations
clinical efficacy
medication safety
